

Are we testing for triple elimination? A review of national guidelines on preventing mother-to-child transmission of HIV, syphilis, and hepatitis B in the African region

Kellie List¹, Aliza Monroe-Wise², Margaret Banks¹, Magdalena Barr-DiChiara², Agnes Chetty³, Morkor Newman-Owiredu², Olufunmilayo Lesi², Cheryl Case Johnson², Alison L. Drake^{1§}

1 Department of Global Health, University of Washington, Seattle, USA

2 World Health Organization, Geneva, Switzerland

3 Regional Office for Africa, Brazzaville, Congo

§ Corresponding author: Alison Drake

University of Washington
3980 15th Ave NE Rm 884
Box 351620
Seattle, WA 98195
Phone: (206) 579-9211

Email: adrake2@uw.edu

E-mail addresses of authors:

KL: klist@uw.edu

AMW: monroewisea@who.int

MB: banksme@uw.edu

MBD: barrdichiam@who.int

AC: chettya@who.int

MNO: newmanm@who.int

OL: lesio@who.int

CJ: johnsonc@who.int

ALD: adrake2@uw.edu

Keywords: elimination of mother-to-child transmission, HIV, syphilis, hepatitis B virus, congenital infections, pregnancy, testing

ABSTRACT

Introduction: World Health Organization (WHO) updated guidelines for maternal HIV, syphilis and hepatitis B virus (HBV) testing for pregnant women, and advised on using dual HIV/syphilis rapid diagnostic tests (RDTs). We reviewed national testing guidelines to assess political support in alignment with WHO guidance and triple elimination of mother-to-child transmission (MTCT) priorities.

Methods: We reviewed national HIV-related guidelines from 46 African countries after 2010, including guidelines on prevention MTCT, HIV testing/self-testing, HIV antiretroviral treatment, and/or HIV pre-exposure prophylaxis. Data was extracted on recommendations for maternal testing for HIV (frequency and timing), syphilis (any test/test type); and HBV. Testing recommendations for all three infections in the most recent country guidelines were compared to WHO guidelines.

Results: Testing policies on HIV, syphilis, or HBV during pregnancy and/or postpartum from 38 (83%) countries were identified; 18 (47%) had policies updated after 2019 and 11 (29%) were high HIV burden. All 38 countries with HIV testing guidelines addressed maternal HIV retesting, while 68% had guidelines recommending syphilis testing (46% of which recommended the dual RDT), and 58% had HBV testing guidelines. Maternal HIV retesting was more frequent than recommended by WHO in 2019 in 9/11 (82%) and 7/27 (26%) of high and low HIV burden countries, respectively. Half of countries had triple elimination of MTCT focused policies, and 10 (26%) had maternal HIV retesting as well as syphilis and/or HBV testing guidance.

Conclusions: Half of countries had guidelines to test for all three infections; policy evaluations to measure implementation and impact are needed.

INTRODUCTION

Triple elimination of mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B virus (HBV) is a critical priority due to the morbidity and mortality associated with mother-to-child transmission (MTCT) with these infections. Approximately 1.3 million women living with HIV become pregnant every year, 900,000 pregnant women are infected with syphilis globally, and 83% of new HBV infections are in Africa or South-east Asia [1]. In 2019, the World Health Organization (WHO) guidelines highlighted maternal testing for HIV, syphilis and HBV, including the use of the dual HIV/syphilis rapid tests [2]. Despite this, national policies and implementation vary widely, with competing priorities and resource limitations acting as barriers to progress.

The prevention of MTCT has seen the most progress in HIV, largely due to dedicated investments which had resulted in widespread HIV testing in antenatal care. As a result, EMTCT efforts will need to build upon the existing international and national policy and funding infrastructure for HIV testing [3].

In contrast, coverage of syphilis and HBV testing in pregnant people lags behind that of HIV. Despite recommendations to test all pregnant people for all three infections, disparities in funding and advocacy have contributed to lower syphilis and HBV testing coverage. In response to this gap, WHO recommends dual HIV/syphilis rapid diagnostic tests (RDTs) and HBV testing for all pregnant people at least once in pregnancy. Dual testing, requiring only one test for both HIV and syphilis infections, can be cost-saving or cost-effective, and capitalize on the high HIV testing coverage to deliver more syphilis testing and treatment to pregnant women [2,4]. Fewer resources and testing options are available for HBV, compared to HIV, making it challenging to progress toward EMTCT goals.

For countries with a high HIV burden, strategies such as catch-up testing for those who miss or delay visits, as well as retesting in the third trimester, are essential components of EMTCT efforts [2]. PrEP is also safe and should be encouraged, given the increased risk of HIV acquisition during these periods [5]. Moreover, partner testing and self-testing approaches have proven effective in reaching male partners of pregnant women [6-7]. However, our prior review of maternal HIV testing guidelines revealed that many countries recommend retesting at suboptimal intervals and frequencies that do not align with WHO guidelines [8]. A modeling study further suggested that retesting more frequently than necessary or at inappropriate times can lead to higher costs with limited impact on HIV transmission prevention [9].

To advance the integration and scale-up of testing for all three infections in alignment with WHO guidance, it is important to assess whether national guidelines support EMTCT goals. This review of guidelines from African countries on maternal testing for HIV, syphilis, and HBV will identify gaps and inform policy planning to enhance implementation efforts and promote EMTCT.

METHODS

HIV guidelines from 46 countries in Africa were reviewed and compared with the 2019 WHO guidelines. Available guidelines published in 2019 or after on prevention of mother-to-child HIV transmission (PMTCT), HIV testing, HIV self-testing, HIV antiretroviral treatment (ART), and/or HIV pre-exposure prophylaxis (PrEP) were included in the review.

Country guidelines were provided by WHO. If countries had multiple guideline documents, we used the most recently published version, or the guideline with the most complete information for each piece of information extracted. We electronically searched country guidelines for terms related to the following topics: HIV testing and retesting, postpartum, pregnancy, syphilis testing, and HBV testing, pregnancy, labour/delivery, postpartum, or lactating/breastfeeding.

No country guidelines were excluded from the current review based on language. Non-English languages included Portuguese, French, and Spanish. All non-English guidelines were reviewed by the first reviewer (MB) using Google translated versions of the guidelines. Reviewers from WHO, fluent in each language, were consulted to interpret translations when necessary.

Primary guideline reviews were conducted by two individuals (MB and KL). Primary reviewers extracted data into a standardized data collection form and switched roles to serve as secondary reviewers to verify abstraction from the other reviewer; discrepancies were resolved by a third reviewer (AD). Data from policies was abstracted on: HIV testing at initial antenatal care (ANC) visit; maternal and partner HIV self-testing; partner HIV and syphilis

testing; HIV retesting during pregnancy, labour/delivery, and/or postpartum; syphilis testing during pregnancy and/or labour/delivery; syphilis test type (rapid diagnostic tests [RDTs] or lab-based testing); confirmatory syphilis tests; HBV testing during pregnancy and/or labour/delivery, HBV test type, and HBV household testing.

HIV retesting Countries were classified as having high (prevalence >5%) or low (prevalence ≤5%) HIV burden as previously described based on the most recent 2022 UNAIDS estimates available for women aged 15-49 years, or for adults aged 15-49 years if not available. Maternal HIV retesting was defined as testing after the first ANC visit (third trimester, at labour/delivery, and/or postpartum). Countries with general population policies for retesting (not specific to pregnancy or postpartum) were classified as not having guidance on maternal HIV retesting.

We also classified countries based on the frequency of HIV retesting recommended by WHO. For high HIV burden countries, HIV retesting was classified as 1) less frequent than the WHO guidelines if they do not recommend retesting at least once during late pregnancy or at labor and delivery and no retesting in the postpartum period, 2) as frequent as the WHO guidelines if they recommended retesting once during late pregnancy (and/or at labor and delivery) and/or 1-2 times in the postpartum period, 3) more frequent than the guidelines if they recommended retesting more than once during late pregnancy (and/or at labor and delivery) and/or more than 2 times in the postpartum period.

For low HIV burden countries, maternal HIV retesting is not universally recommended by WHO. In these settings it is advised that HIV-negative women be retested in the third trimester if they are in serodiscordant relationships with partners on ART with unsuppressed viral load, or have ongoing risk; and during the postpartum period for women from these groups or who are from a key population. For low HIV burden settings, countries are classified as 1) less frequent than guidelines if they do not recommend retesting for these special groups of women, 2) as frequent if they recommend one retest during late pregnancy, with or without an additional postpartum retest, and 3) more frequent for countries who recommend >1 retest during late pregnancy and/or >1 retest postpartum for these special groups of women or for all women.

Syphilis testing Syphilis testing was classified as laboratory based, individual RDT, or dual RDT. The laboratory test types included venereal disease research laboratory test (VDRL), rapid plasma reagin (RPR), or treponema pallidum hemagglutination assay (TPHA). RDTs included both the individual syphilis RDT or the dual HIV/syphilis RDT. Confirmatory testing for syphilis was defined as any test (laboratory or RDT) to confirm a positive test result. We extracted data on whether syphilis testing was recommended at specific time points during pregnancy and postpartum, and if male partner testing was included.

HBV testing We classified guidelines based on populations recommended for HBV testing as follows: general population, pregnant women, people living with HIV (PLHIV), pregnant women with HIV, and key populations. We captured data on HBV test type, and HBV household testing, which is inclusive of partner testing recommendations.

RESULTS

Overview of country policies

Of 46 countries in the review, 12 (26%) were from high HIV burden settings. Overall, 38 (83%) countries had integrated HIV testing guidelines covering HIV, syphilis, and/or HBV during pregnancy and/or postpartum periods (Table 1); 18 (47%) of these had guidelines updated after 2019. Three of eight countries (3 low HIV burden) with no testing guidelines for any of the three infections were updated after 2019 while five countries (1 high HIV burden, 4 low HIV burden) had guidelines published prior to or during 2019.

HIV retesting

All 38 countries with policies identified had maternal HIV retesting guidelines. Overall, 18 (47%) had retesting guidelines that aligned with WHO guidance, while 16 (42%) had guidelines that recommended more frequent testing, and 3 (8%) were less frequent. Among 11 high HIV burden countries, no countries were fully aligned with WHO guidelines, while 2 (18%) were less frequent and 9 (82%) were more frequent. In contrast, among 27 low HIV burden countries, 19 (70%) were as frequent as WHO guidance, while 1 (3%) was less frequent and 7 (26%) were more frequent. Among 18 (6 high and 12 low HIV burden) countries with guidelines updated after 2019, 8 (44%) were more frequent (5 high and 3 low HIV burden) while 9 (50%) were as frequent (9 low HIV burden) and

6% (1 high HIV burden) were less frequent than WHO guidelines. Of 38 countries with any testing guidelines, 58% had guidelines on maternal HIV self-testing (HIVST), 74% had partner HIV testing guidelines, and 61% had guidelines on PrEP in pregnancy.

Syphilis

testing

Among 38 countries with available HIV guidelines, 26 (68%) also had guidelines for pregnant women to be tested for syphilis: 6 (23%) identified lab-based tests, 12 (46%) recommended dual RDT (3 of 12 [25%] which recommend lab-based confirmatory syphilis testing for diagnosis for women with reactive RDT results), and 7 (27%) did not specify the test type (Figure 1). Among the 12 countries who recommend the dual RDT, all 12 recommend it as the first ANC test (46% of all countries with syphilis test recommendations). Among the 18 countries with guidelines updated after 2019, 15 (83%) recommend syphilis testing in pregnancy, 11 of which (61%) recommended the dual RDT. In addition, 35% of countries with syphilis testing recommended syphilis partner testing and 42% recommended syphilis retesting in pregnancy.

HBV testing

Twenty-two (58%) of 38 countries with any guidelines recommended maternal HBV testing, 13 (59%) of which specified using HBsAg specifically, while the other countries did not indicate test type. In addition, three countries (14%) recommended testing of household members.

Progress towards testing for triple EMTCT

Among 38 countries with any testing guidance, 19 (50%) have maternal HIV retesting, syphilis testing, and HBV testing guidelines; Ten additional countries (26%) have maternal HIV retesting, and either syphilis testing or HBV testing guidelines; 9 (24%) only had maternal HIV retesting guidance (Table 1).

DISCUSSION

Our review of national guidelines across sub-Saharan Africa indicates that while significant progress has been made toward EMTCT of HIV, syphilis, and HBV, gaps remain in policy adoption and implementation. The high coverage of HIV testing and maternal retesting reflects strong political and financial commitments, built on decades of international support for HIV prevention. This progress has not been mirrored in syphilis and HBV testing, however, which lag behind.

A key finding is that while 83% of countries with policies reviewed had PMTCT-related testing guidance for HIV, syphilis, and/or HBV, a little more than half of the country policies reviewed had guidance for HIV retesting, syphilis or HBV during pregnancy, signaling uneven efforts toward triple elimination. The lower adoption of syphilis and HBV testing guidelines highlights disparities in funding streams, advocacy, and the prioritization of non-HIV infections within maternal care frameworks.

HIV retesting practices appeared to vary widely, with some countries retesting too frequently and at suboptimal time points, leading to inefficient use of resources. Our review echoes modeling studies that suggest increasing the frequency of HIV retesting beyond WHO recommendations does not result in meaningful public health impact [4, 9]. Conversely, in 18% of high HIV burden countries, HIV retesting occurs too infrequently. These discrepancies suggest greater efforts to align national policies and allocation of resources are needed. Redirecting resources from excessive HIV retesting to increase syphilis and HBV testing could be more impactful and further accelerate progress toward EMTCT.

Despite the well-documented morbidity and mortality associated with congenital syphilis, maternal syphilis testing remains significantly lower than HIV testing [10]. Integrated HIV and syphilis testing, particularly with rapid or self-tests which enable same day diagnosis and treatment, have been proposed as a way to overcome existing testing barriers (e.g. limited access to lab-settings and long wait times). Dual tests are cost-effective and efficient [11-13], yet only 62% of countries have adopted them within antenatal care [15]. This low uptake, coupled with the fact only 42% of countries updated their syphilis testing policies following the 2019 WHO guidelines, indicates missed opportunities to expand dual testing persist. With three WHO prequalified dual tests, some under \$1.00, integration into national policies must be prioritized to address stagnant and rising congenital syphilis rates [16].


HBV testing, key to triple elimination, has also seen limited uptake [17-18]. Only a little more than half (58%) of countries with HIV guidelines had specific guidance HBV testing in pregnancy; even fewer provided guidance on

follow-up tests (e.g. HBsAg or HBV DNA) to guide antiviral prophylaxis. Given the high HBV burden in sub-Saharan Africa, the lack of testing guidelines represents a critical gap for the future of EMTCT efforts in the region. With the 2024 WHO update on HBV testing and treatment [19], it will be important to review policy changes and assess their impact on HBV transmission rates.

Our review highlights both progress and gaps in testing policies for HIV, syphilis, and HBV. Testing serves as the entry point for prevention and treatment, making it crucial to EMTCT. While triple elimination is a global priority, our study was limited by its focus on sub-Saharan Africa countries with available testing-related guidelines. It also did not include sexually transmitted infections (STIs) more broadly or HBV-specific guidelines beyond those related to HIV. Nonetheless, the findings underscore the importance of integrating testing policies across all three infections to optimize maternal and infant health outcomes and contribute to triple elimination.

To move toward EMTCT of HIV, syphilis, and HBV, countries must not only update their testing guidelines to align with WHO recommendations, but also ensure effective implementation. Optimizing and sustaining existing, as well as targeted expansion, of HIV testing during pregnancy remains critical for elimination goals. In parallel, addressing the gaps in syphilis and HBV testing requires greater focus, advocacy, policy updates and dedicated funding. By strengthening and integrating testing frameworks across all three infections, we can reduce infant morbidity and mortality from these preventable infections. Efforts are now needed to achieve the WHO global health sector strategy to end AIDS and ongoing STIs and viral hepatitis epidemics by 2030 [20].

Figure 1 - Syphilis test type in pregnancy (n=26)*



*12 of 38 countries (32%) with any guidelines were excluded as they did not have syphilis testing guidelines.

Table 1 - Maternal testing guidelines supporting triple EMTCT, by country (n=38)

	Algeria	Angola	Benin	Botswana	Burkina Faso	Burundi	Cameroon	Central African Rep.	Cote d'Ivoire	DRC	Equatorial Guinea	Eritrea	Eswatini	Ethiopia	Gabon	Gambia	Ghana	Guinea	Kenya	Lesotho	Liberia	Madagascar	Mali	Mauritania	Mozambique	Namibia	Nigeria	Rwanda	Senegal	Seychelles	Sierra Leone	South Africa	South Sudan	Tanzania	Togo	Uganda	Zambia	Zimbabwe			
HIV retesting guidelines*	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	
Syphilis testing guidelines	✓	✓		✓		✓				✓			✓			✓	✓		✓	✓	✓	✓			✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓	
HBV testing guidelines	✓	✓			✓	✓	✓				✓	✓	✓			✓			✓	✓	✓	✓				✓	✓	✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	✓	✓	✓
	Green = Triple elimination momentum: Maternal HIV retesting, syphilis testing, and HBV testing: 50% Yellow = Dual elimination momentum: Maternal HIV retesting, and either syphilis testing or HBV testing 26% Gray = HIV elimination momentum or HBV elimination momentum only: 24% *Retesting guidance in ANC, delivery, and/or postpartum/while breastfeeding																																								

REFERENCES

1. Introducing a framework for implementing triple elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus: policy brief. Geneva: World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO.
2. Consolidated guidelines on HIV testing services, 2019. Geneva: World Health Organization; 2020.
3. Hensen B, Baggaley R, Wong VJ, et al. Universal voluntary HIV testing in antenatal care settings: a review of the contribution of provider-initiated testing & counselling. *Trop Med Int Health*. 2012;17(1):59-70. doi:10.1111/j.1365-3156.2011.02893.x
4. Rodriguez PJ, Roberts DA, Meisner J, Sharma M, Owiredu MN, Gomez B, et al. Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study. *The Lancet Global Health*. 2021 Jan;9(1):e61–71.
5. WHO Technical brief: Preventing HIV during pregnancy and breastfeeding in the context of pre-exposure prophylaxis (PrEP). Geneva: World Health Organization; 2017. License: CC BY-NC-SA 3.0 IGO.
6. Johnson CC, Kennedy C, Fonner V, et al. Examining the effects of HIV self-testing compared to standard HIV testing services: a systematic review and meta-analysis. *J Int AIDS Soc*. 2017;20(1):21594. doi:10.7448/IAS.20.1.21594
7. Drake AL, Jiang W, Kitao P, Farid S, Richardson BA, et al. (2024) Preferences and uptake of home-based HIV self-testing for maternal retesting in Kenya. *PLOS ONE* 19(8): e0302077. <https://doi.org/10.1371/journal.pone.0302077>
8. Drake AL, Thomson KA, Quinn C, Newman Owiredu M, Nuwagira IB, Chitembo L, Essajee S, Baggaley R, Johnson CC. Retest and treat: a review of national HIV retesting guidelines to inform elimination of mother-to-child HIV transmission (EMTCT) efforts. *J Int AIDS Soc*. 2019 Apr;22(4):e25271. doi: 10.1002/jia2.25271. PMID: 30958644; PMCID: PMC6452920.
9. Meisner J, Roberts DA, Rodriguez P, Sharma M, Newman Owiredu M, Gomez B, et al. Optimizing HIV retesting during pregnancy and postpartum in four countries: a cost-effectiveness analysis. *J Intern AIDS Soc*. 2021 Apr;24(4):e25686.
10. Korenromp EL, Rowley J, Alonso M, Mello MB, Wijesooriya NS, Mahiané SG, et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes—Estimates for 2016 and progress since 2012. Vellakkal S, editor. *PLoS ONE*. 2019 Feb 27;14(2):e0211720.
11. Graybill LA, Kasaro M, Freeborn K, Walker JS, Poole C, Powers KA, Mollan KR, Rosenberg NE, Vermund SH, Mutale W, Chi BH. Incident HIV among pregnant and breast-feeding women in sub-Saharan Africa: a systematic review and meta-analysis. *AIDS*. 2020 Apr 1;34(5):761-776. doi: 10.1097/QAD.0000000000002487. PMID: 32167990; PMCID: PMC7275092.
12. Penumetsa M, Neary J, Farid S, et al. Implementation of HIV Retesting During Pregnancy and Postpartum in Kenya: A Cross-Sectional Study. *Glob Health Sci Pract*. 2022;10(1):e2100451. Published 2022 Feb 28. doi:10.9745/GHSP-D-21-00451
13. Baker U, Okuga M, Waiswa P, Manzi F, Peterson S, Hanson C; EQUIP study group. Bottlenecks in the implementation of essential screening tests in antenatal care: Syphilis, HIV, and anemia testing in rural Tanzania and Uganda. *Int J Gynaecol Obstet*. 2015 Jun;130 Suppl 1:S43-50. doi: 10.1016/j.ijgo.2015.04.017. Epub 2015 Apr 29. PMID: 26054252.
14. WHO HIV policy adoption and implementation status in countries, 2024 [Internet]. World Health Organization; 2024 Dec [cited 2024 Oct 18]. Available from: https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/j0482-who-ias-hiv_factsheet_v3-2.pdf?sfvrsn=20d9d0fb_1
15. UNAIDS DATA 2020 [Internet]. Geneva: Joint United Nations Programme on HIV/AIDS; 2020. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf
16. New reduced costs of dual HIV/syphilis rapid tests to accelerate progress toward elimination of mother-to-child transmission of HIV and syphilis [Internet]. 2021 [cited 2024 Oct 15]. Available from: <https://www.who.int/news/item/15-11-2021-new-reduced-costs-of-dual-hiv-syphilis-rapid-tests-to-accelerate-progress-toward-emtct-of-hiv-and-syphilis>.
17. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO.
18. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024. Licence: CC BYNC-SA 3.0 IGO.
19. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024. Licence: CC BYNC-SA 3.0 IGO.

20. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
21. CENTRO NACIONAL DE ENDEMIAS PROGRAMA NACIONAL DE LUTA CONTRA A TUBERCULOSE, HIV, ITS e Hepatite LEPROSA. REPÚBLICA DEMOCRÁTICA DE S. TOMÉ E PRÍNCIPE, Ministério da Saúde; 2020.
22. CONSOLIDATED GUIDELINES FOR HIV CARE IN GHANA. Republic of Ghana, Ministry of Health; 2019 Aug.
23. CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND AIDS IN UGANDA. Ministry of Health, The Republic of Uganda; 2020 Feb.
24. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care in Sierra Leone. Ministry of Health and Sanitation, Sierra Leone; 2020.
25. Direction Nationale de la Sante Service de Prevention et de Controle des Maladies Prioritaires. 2020 Jan.
26. Directives Nationales Pour le Conseil et Depistage du VIH au Burundi. 2020 Jan.
27. REPUBLIQUE CENTRAFRICAINE, MINISTERE DE LA SANTE ET DE LA POPULATION. DIRECTIVES NATIONALES SUR L'UTILISATION DES ANTIRETROVIRAUX POUR LA PREVENTION ET LE TRAITEMENT DE L'INFECTION A VIH EN REPUBLIQUE CENTRAFRICAINE. 2018 Sep.
28. DOCUMENT DE POLITIQUE, NORMES ET PROCEDURES DU CONSEIL ET DEPISTAGE DU VIH AU TOGO. RÉPUBLIQUE TOGOLAISE; 2019 Mai.
29. El Guía integrada del uso de antirretrovirales para la prevención y el tratamiento de la infección VIH. Ministerio de Sanidad y Bienestar Social; 2018.
30. Eritrea National Guidelines for HIV Testing Services (HIV). Ministry of Health, Dept. of Public Health; 2019 Apr.
31. Republique du Cameroun. Guide de Poche sur la Prise en Charge du VIH, 2019. 2019.
32. GUIDE NATIONAL DU CONSEIL ET DEPISTAGE DU VIH. REPUBLIQUE GABONAISE; 2017 Mar.
33. GUIDE NATIONAL DU DÉPISTAGE DU VIH. REPUBLIQUE DE GUINEE, MINISTERE DE LA SANTE; 2019 Oct.
34. Ministry of Health. Handbook of the Botswana 2016 Integrated HIV Clinical Care Guidelines. Republic of Botswana; 2016.
35. HIV TESTING ALGORITHM FOR PREGNANT WOMEN IN ANC SETTINGS. Ministry of Health & Child Care, Zimbabwe; 2021 Feb.
36. HIV TESTING SERVICES NATIONAL GUIDELINES. REPUBLIC OF ZAMBIA, MINISTRY OF HEALTH; 2020.
37. HIV/AIDS National Strategic Plan for Ethiopia, 2021-2025. Federal HIV/AIDS Prevention and Control Office (FHAPCO); 2021.
38. Instituto Nacional de Luta Contra a SIDA. Normas de Tratamento Antiretroviral. Luanda: Republica de Angola: Ministerio da Saude; 2015.
39. Instruction N 06 du Fixant Les Directives Nationales du Diagnostic Biologique l'Infection VIH. Republique Algerienne Democratique et Populaire; 2013 Apr.
40. Kenya HIV Prevention and Treatment Guidelines, 2022. Ministry of Health, National AIDS & STI Control Program (NASCOP); 2022.
41. Malawi Clinical HIV Guidelines. Ministry of Health and Population, Malawi; 2018.
42. Mauritius HIV Testing Guidelines. Virology STI/AIDS Reference Laboratory; 2021.
43. NATIONAL COMPREHENSIVE GUIDELINES ON HIV TESTING SERVICES. UNITED REPUBLIC OF TANZANIA, MINISTRY OF HEALTH; 2019 Jan.
44. NATIONAL CONSOLIDATED GUIDELINES FOR THE MANAGEMENT OF HIV IN ADULTS, ADOLESCENTS, CHILDREN AND INFANTS AND PREVENTION OF MOTHER-TO-CHILD TRANSMISSION. South African National Department of Health; 2020 Feb.
45. NATIONAL GUIDELINES FOR HIV PREVENTION, TREATMENT AND CARE. NATIONAL AIDS AND STIs CONTROL PROGRAMME, FEDERAL MINISTRY OF HEALTH NIGERIA; 2020.
46. National Guidelines for HIV Testing Services (HTS) & Psycho-Social Support (PSS). Republic of Liberia, Ministry of Health; 2020 Jun.
47. National Guidelines for Prevention and Management of HIV. Republic of Rwanda, Ministry of Health; 2018.
48. NATIONAL GUIDELINES FOR THE ELIMINATION OF MOTHER TO CHILD TRANSMISSION OF HIV AND SYPHILIS. Government of Lesotho, Ministry of Health; 2020 Oct.
49. National Guidelines on HIV Testing Services. Republic of Namibia, Ministry of Health and Social Services;

- 2018.
50. Republic of Congo. NATIONAL STRATEGIC FRAMEWORK AIDS RESPONSE 2019-2022. 2019 Feb.
 51. NATIONAL STRATEGIC PLAN FOR HIV AND AIDS, THE GAMBIA (2021-2025). Government of The Republic of The Gambia; 2020.
 52. NORMES ET DIRECTIVES NATIONALES EN CONSEIL ET DEPISTAGE DU VIH AU TCHAD. 2017 Oct.
 53. NORMES ET PROCEDURES DES SERVICES DE DEPISTAGE DU VIH AU MALI. RÉPUBLIQUE DU MALI; 2017 Juillet.
 54. NORMES ET PROCEDURES RELATIVES AUX INTERVENTIONS DE PREVENTION DE LA TRANSMISSION MERE-ENFANT DU VIH, SYPHILIS, ET HEPATITES A MADAGASCAR. Repoblikan'i Madagasikara; 2020.
 55. Normes et Protocoles de Prise en Charge Medicale des Personnes Vivant Avec le VIH au Burkina Faso. 2021 Juin.
 56. Union des Comores. PLAN STRATEGIQUE NATIONAL DE LUTTE CONTRE LES IST/VIH/SIDA « 2021 – 2025 ». 2021 Avril.
 57. Plano Nacional de Tripla Eliminação da Transmissão vertical do HIV, Sífilis e Hepatite B em Moçambique 2020-2024. RERÚBLICA DE MOÇAMBIQUE MINISTÉRIO DA SAÚDE; 2020.
 58. POLITIQUE, NORMES ET PROTOCOLES DES SERVICES DE DEPISTAGE DU VIH. République du Sénégal; 2018.
 59. Prevention of Mother-to-Child Transmission of HIV. Republic of Seychelles; 2019.
 60. Programa Nacional de Luta contra as IST/VIH/SIDA e Hepatites Virais (PNLS/HV). Governo da Guine-Bissau; 2021 Sep.
 61. Programme National de Lutte contre le sida. REPUBLIQUE DE COTE D'IVOIRE; 2019.
 62. PROGRAMME NATIONAL DE LUTTE CONTRE LE SIDA. REPUBLIQUE DEMOCRATIQUE DU CONGO; 2020 Sep.
 63. Revised National HIV and AIDS Strategic Plan 2021-2023. The Republic of South Sudan; 2020 Aug.
 64. Ministério da Saúde e da Segurança Social. Serviço para a Prevenção e Controlo de Doenças Prioritárias Programa de Luta contra as Doenças de Transmissão Sexual, incluindo o VIH/Sida. 2019 Jan.
 65. STRATEGIE DE DEPISTAGE DU VIH EN MAURITANIE. 2020 Juin.
 66. Strategie Nationale de Demedicalisation du Depistage du VIH au Benin. 2017 Dec.
 67. Stratégie nationale de dépistage du VIH différenciée et sa mise en œuvre. 2020 Février.
 68. Swaziland Integrated HIV Management Guidlines. Swaziland Ministry of Health; 2018.
 69. ZAMBIA CONSOLIDATED GUIDELINES for Treatment and Prevention of HIV Infection. Republic of Zambia, Ministry of Health; 2020.